Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer. Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr […]

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer. Shuttleworth S.J., Bone E.A; Cecil A.R.L., Colman L., Fulton R., Hill T.J., McCormick S., Nodes W.J., Rogers H., Silva F.A., Tomassi C.D., Whale A.D. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; […]

Karus Therapeutics presenting at AACR Annual Meeting 2014

Oxford, UK, 3 April 2014 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in San Diego, 5-9th April 2014. Stephen Shuttleworth, Karus’s CSO, will present two posters describing the […]